The association between serum anti-HSP27 levels with hypertriglyceridemia

There are little data on isolated hypertriglyceridemia and CVD risk. Heat shock protein 27 (Hsp27) is one of the heat shock proteins (Hsps) with low molecular weight. It has been shown that the atherosclerosis patients have higher concentrations of anti-Hsp auto-antibodies. The aim of the current study was to assess the relationship between hypertriglyceridemia with serum anti-Hsp27 titres. In this cross-sectional study, fasting serum lipid profile and anthropometric parameters of 1688 subjects (1113 subjects with and 575 without hypertriglyceridemia) aged 35–65 years were analyzed as part of the data derived from the Mashhad stroke and heart atherosclerotic disorders (MASHAD: 2010–2020). A validated questionnaire was used to collect the demographic data. Combined dyslipidemia was defined according to the NCEP ATPIII criteria. There were significant differences in waist and hip circumferences, level of fasting blood glucose, hs-CRP, systolic and diastolic blood pressure (p < 0.001 for all variables), between individuals with isolated hypertriglyceridemia (IHTG), those with combined dyslipidemia and control groups. After adjusting for confounding factors, logistic regression analysis showed that high levels of serum anti-Hsp 27 were associated with a lower odds of HTG risk (OR:0.62, 95% CI (0.39–0.97), p: 0.03). We found that serum anti-HSP27 antibody titers were significantly lower in the HTG group compared with individuals without HTG. However, levels of serum anti-HSP27 antibody can be affected by drug treatment. Therefore, the evaluation of drug treatment on the serum anti-HSP27 antibody in a larger population can help to confirm these findings.